James C. Momtazee's most recent trade in BridgeBio Pharma Inc was a trade of 8,425 Stock Option (Right to Buy) done . Disclosure was reported to the exchange on June 20, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| BridgeBio Pharma Inc | James C. Momtazee | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Jun 2025 | 8,425 | 8,425 | - | - | Stock Option (Right to Buy) | |
| BridgeBio Pharma Inc | James C. Momtazee | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Jun 2025 | 6,589 | 95,080 (0%) | 0% | 0 | Common Stock | |
| Roivant Sciences Ltd | James C. Momtazee | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Apr 2025 | 1,379 | 95,986 | - | 0 | Common Shares | |
| Roivant Sciences Ltd | James C. Momtazee | Director | Payment of exercise price or tax liability using portion of securities received from the company at price $ 10.15 per share. | 17 Apr 2025 | 276 | 95,710 | - | 10.1 | 2,801 | Common Shares |
| Roivant Sciences Ltd | James C. Momtazee | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Jan 2025 | 1,248 | 94,913 | - | 0 | Common Shares | |
| Roivant Sciences Ltd | James C. Momtazee | Director | Payment of exercise price or tax liability using portion of securities received from the company at price $ 11.21 per share. | 23 Jan 2025 | 306 | 94,607 | - | 11.2 | 3,430 | Common Shares |
| Roivant Sciences Ltd | James C. Momtazee | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Oct 2024 | 1,231 | 93,665 | - | 0 | Common Shares | |
| Roivant Sciences Ltd | James C. Momtazee | Director | Other type of transaction at price $ 12.12 per share. | 12 Sep 2024 | 3,056 | 92,434 | - | 12.1 | 37,039 | Common Shares |
| Roivant Sciences Ltd | James C. Momtazee | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Sep 2024 | 27,894 | 27,894 | - | - | Stock Option (Right to Buy) | |
| Roivant Sciences Ltd | James C. Momtazee | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Sep 2024 | 16,406 | 95,490 | - | 0 | Common Shares | |
| Roivant Sciences Ltd | James C. Momtazee | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Jul 2024 | 1,555 | 79,091 | - | 0 | Common Shares | |
| BridgeBio Pharma Inc | James C. Momtazee | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Jun 2024 | 26,014 | 26,014 | - | - | Stock Option (Right to Buy) | |
| Roivant Sciences Ltd | James C. Momtazee | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Apr 2024 | 1,490 | 77,829 | - | 0 | Common Shares | |
| Roivant Sciences Ltd | James C. Momtazee | Director | Payment of exercise price or tax liability using portion of securities received from the company at price $ 10.90 per share. | 24 Apr 2024 | 293 | 77,536 | - | 10.9 | 3,194 | Common Shares |
| Roivant Sciences Ltd | Momtazee James C. | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 19 Jan 2024 | 1,570 | 76,339 | - | 0 | Common Shares | |
| Roivant Sciences Ltd | James C. Momtazee | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jul 2023 | 1,664 | 62,789 | - | 0 | Common Shares | |
| BridgeBio Pharma Inc | James C. Momtazee | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Jun 2023 | 51,501 | 51,501 | - | - | Stock Option (right to buy) | |
| Roivant Sciences Ltd | James C. Momtazee | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Apr 2023 | 1,351 | 61,125 | - | 0 | Common Shares | |
| Roivant Sciences Ltd | James C. Momtazee | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jan 2023 | 2,447 | 59,774 | - | 0 | Common Shares | |
| Roivant Sciences Ltd | James C. Momtazee | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Oct 2022 | 3,404 | 57,327 | - | 0 | Common Shares | |
| Roivant Sciences Ltd | James C. Momtazee | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Sep 2022 | 68,897 | 68,897 | - | - | Stock Option (Right to Buy) | |
| Roivant Sciences Ltd | James C. Momtazee | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Sep 2022 | 50,000 | 53,923 | - | 0 | Common Shares | |
| Roivant Sciences Ltd | James C. Momtazee | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Jul 2022 | 3,923 | 3,923 | - | 0 | Common Shares | |
| BridgeBio Pharma Inc | James C. Momtazee | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 Jun 2022 | 104,921 | 104,921 | - | - | Stock Option (right to buy) | |
| BridgeBio Pharma Inc | James C. Momtazee | Director | Purchase of securities on an exchange or from another person at price $ 14.50 per share. | 29 Dec 2021 | 80,000 | 88,491 (0%) | 0% | 14.5 | 1,160,000 | Common Stock |
| BridgeBio Pharma Inc | James C. Momtazee | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Jun 2021 | 38,895 | 38,895 | - | - | Stock Option (right to buy) |